Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MK-0653, ezetimibe
MK0653, ezetimibe · 16 trials · 8 indications
| Name | Type | Description |
|---|---|---|
| MK0653, ezetimibe / Duration of Treatment: 4 Weeks | DRUG | - |
| MK0653, ezetimibe / Duration of Treatment: 6 Weeks | DRUG | - |
| MK0653, ezetimibe | DRUG | - |
| Comparator: placebo | DRUG | - |
| MK-0653, ezetimibe | DRUG | - |
| Duration of Treatment: 3 months | DRUG | - |
| Comparator: ezetimibe, placebo | DRUG | - |
| Comparator: fenofibrate monotherapy | DRUG | - |
| Comparator: statins | DRUG | - |
| MK0653, ezetimibe / Duration of Treatment: 28 weeks | DRUG | - |
| Comparator: atorvastatin / Duration of Treatment: 28 weeks | DRUG | - |
| MK0653, ezetimibe / Duration of Treatment: 27 Weeks | DRUG | - |
| MK0733, simvastatin / Duration of Treatment: 27 Weeks | DRUG | - |
| Comparator: simvastatin / Duration of Treatment: 27 Weeks | DRUG | - |
| MK0653, ezetimibe / Duration of Treatment: 30 Weeks | DRUG | - |
| Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks | DRUG | - |
Inclusion Criteria: * Men or women \>18 and \<80 years of age * Patients receiving statin therapy for a minimum period of 6 weeks prior to visit 1 * Female patients receiving hormone therapy (including hormone replacement therapy, any estrogen antagonist/agonist, or oral contraceptives) if maintain...
MK0653, ezetimibe is a small molecule drug developed by Organon & Co. (ticker OGN) that is in Phase 3 clinical development. It has been studied across cardiovascular and metabolic conditions, including coronary disease, type 2 diabetes mellitus, hypercholesterolemia, hypercholesterolaemia, and inborn errors of lipid metabolism.
MK0653, ezetimibe has been studied for coronary disease, type 2 diabetes mellitus, hypercholesterolemia, hypercholesterolaemia, and inborn errors of lipid metabolism. Trials have evaluated it both as a single agent and in combination with simvastatin, including in patients at risk for heart disease and in patients with type 2 diabetes.
MK0653, ezetimibe is developed by Organon & Co., which trades under the ticker OGN. Organon is the sponsor associated with the clinical trial program for this asset, which includes ten completed studies enrolling a total of 6,977 participants.
MK0653, ezetimibe is in Phase 3 development. All ten of its listed clinical trials are Phase 3 studies, and all ten are completed, with no active trials currently listed. The program has enrolled 6,977 participants in total.
Completed Phase 3 trials include NCT00551876, which compared simvastatin alone with simvastatin plus ezetimibe in type 2 diabetic patients, and NCT00551447, which compared ezetimibe plus simvastatin with simvastatin alone in patients at risk for heart disease. Other studies include NCT00457275 and NCT00395473 in hypercholesterolemia.
Yes, MK0653 and ezetimibe refer to the same drug. MK0653 is the compound designation used in the trial registry entries, while ezetimibe is the drug name. Registry listings also append duration-of-treatment labels such as 4 weeks, 6 weeks, 27 weeks, 28 weeks, and 30 weeks to distinguish individual studies.